ArticleJournal of arrhythmia2025
Long-Term Safety of Extremely Low-Dose Amiodarone at 50 mg Daily in Patients With Persistent Atrial Fibrillation.
Article in Journal of arrhythmia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Reply to "Challenges to the Long-Term Safety Claims of Extremely Low-Dose Amiodarone: Pulmonary, Thyroid, Hepatic, and Statistical Concerns".Journal of arrhythmia · 2025Article
- Long-Term Safety of Extremely Low-Dose Amiodarone at 50 mg Daily in Patients With Persistent Atrial Fibrillation.Journal of arrhythmia · 2025Article
- Challenges to the Long-Term Safety Claims of Extremely Low-Dose Amiodarone: Pulmonary, Thyroid, Hepatic, and Statistical Concerns.Journal of arrhythmia · 2025Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rhythm control of atrial fibrillation (AF) by pulmonary vein isolation alone is commonly difficult in this aging society, and the role of pharmacological therapy is being revisited. Identifying the lowest dose of amiodarone is important as this drug causes dose- and duration-related lung toxicity. Long-term safety of the use of extremely low-dose amiodarone in Japanese patients was retrospectively evaluated. Methods: Included were 120 patients treated with extremely low-dose amiodarone (50 mg daily) for persistent AF. KL-6 level was systematically measured at baseline and every 3 months thereafter. The patients were classified into a different quartiles (Q) based on the KL-6 level measured at baseline (Q1, Q2, Q3, and Q4). Thyroid function was also evaluated at each follow-up. Results: During a mean follow-up period of 51 months, KL-6 elevation (> 700 U/mL) occurred in 7 (5.8%) patients with higher baseline KL-6 (Q1, 0 patients; Q2, 0 patients; Q3, 1 patient; and Q4, 6 patients; Conclusions: Even an extremely low dose of amiodarone may potentially contribute to maintenance of sinus rhythm in highly selected patients with persistent AF. A low baseline KL-6 level may indicate patients at lower risk for amiodarone-related IP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.